drug_type
RELEVANT_DRUG
intervention_type
Biologic (monoclonal antibody)
drug_description
Chimeric IgG1 monoclonal antibody that binds and neutralizes TNF-alpha (soluble and transmembrane) to reduce inflammatory signaling.
nci_thesaurus_concept_id
C1789
nci_thesaurus_preferred_term
Infliximab
nci_thesaurus_definition
A recombinant chimeric, mouse-human monoclonal antibody directed against tumor necrosis factor alpha (TNF-alpha), a protein involved in inflammation, cell survival, and apoptosis. Infliximab may be pro- apoptotic or anti-apoptotic, depending on cell type. (NCI04)
drug_mesh_term
Infliximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric IgG1 monoclonal antibody that binds both soluble and transmembrane TNF-α, neutralizing TNF and preventing TNFR1/2 activation. This suppresses downstream NF-κB–driven inflammatory signaling and cytokine production; may also mediate Fc-dependent effector functions (ADCC/CDC) against TNF-expressing cells.
drug_name
Infliximab
nct_id_drug_ref
NCT06447870